Franch-Nadal, J.; Mata-Cases, M.; Ortega, E.; Real, J.; Gratacòs, M.; Vlacho, B.; Vallés, J.A.; Mauricio, D.
Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia. J. Clin. Med. 2019, 8, 1389.
https://doi.org/10.3390/jcm8091389
AMA Style
Franch-Nadal J, Mata-Cases M, Ortega E, Real J, Gratacòs M, Vlacho B, Vallés JA, Mauricio D.
Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia. Journal of Clinical Medicine. 2019; 8(9):1389.
https://doi.org/10.3390/jcm8091389
Chicago/Turabian Style
Franch-Nadal, Josep, Manel Mata-Cases, Emilio Ortega, Jordi Real, Mònica Gratacòs, Bogdan Vlacho, Joan Antoni Vallés, and Dídac Mauricio.
2019. "Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia" Journal of Clinical Medicine 8, no. 9: 1389.
https://doi.org/10.3390/jcm8091389
APA Style
Franch-Nadal, J., Mata-Cases, M., Ortega, E., Real, J., Gratacòs, M., Vlacho, B., Vallés, J. A., & Mauricio, D.
(2019). Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia. Journal of Clinical Medicine, 8(9), 1389.
https://doi.org/10.3390/jcm8091389